On Wednesday, the company announced that it received tentative approval for its Arformoterol Tartrate Inhalation Solution from the US drug regulator. The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).
Following the development, Lupin shares gained 1.62% to Rs 868.10 before falling to Rs 823.